Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
Newsroom
Recent News
Archives
E-Alerts
Press Kit
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
E-Alerts
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Email:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

Newsroom

Nutra Pharma Announces ReceptoPharm to Be a Featured Speaker at the 11th Annual Immunobiology Symposium
September 21, 2006

Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has announced that its holding, ReceptoPharm, has been invited to be a featured speaker at the 11th Annual Immunobiology Symposium in Tahoe City, California.

“It is an honor to have the opportunity to speak at this Symposium,” commented Dr. Paul Reid, CEO of ReceptoPharm, Inc. “We are planning to discuss our research and findings on the treatment of Multiple Sclerosis (MS) using our lead drug candidate, RPI-78M,” he added.

In 2005, ReceptoPharm completed a study of RPI-78M in an animal model of Multiple Sclerosis. EAE (experimental allergic encephalomyelitis) is the standard benchmark animal methodology for the study of MS. ReceptoPharm's drug, RPI-78M, proved to be very effective in preventing the onset of disability in acute and chronic models of the disease.

“This Symposium will be a perfect opportunity for ReceptoPharm to highlight their findings and discuss their upcoming clinical trials,” explained Rik J. Deitsch, Chairman and CEO of Nutra Pharma. “ReceptoPharm is preparing to begin their Phase IIb human clinical trial for Adrenomyeloneuropathy (AMN) and they are currently working with the FDA to seek approval to begin their Phase II human clinical trial for MS,” he concluded.

There has been a great deal of interest surrounding research in Multiple Sclerosis therapies. Currently there are five drugs prescribed for the treatment of the disease, representing a market of more than $2 billion. The most recently available drug, Tysabri, was voluntarily pulled from the marketplace in February 2005 by the drug's manufacturers, Biogen-Idec and Elan. It was later allowed to return to the market, but is now required to display a “black box” warning.

The 11th Annual Immunobiology Symposium is sponsored and coordinated by the Baylor College of Medicine and will take place from September 20-24, 2006. Other featured speakers include researchers from the National Institute of Health, Allergan, Los Alamos National Laboratory, the University of British Columbia, and the University of California.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The presentation at the Immunobiology Conference should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


 
Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.
 

 

 
Recent News
 
June 21, 2017
Nutra Pharma Announcing Launch of Luxury Feet


June 07, 2017
Nutra Pharma Featured on Univision's Spanish-Language News Show: Primer Impacto


May 31, 2017
Nutra Pharma Announces Collaboration with the University of Maryland Bioprocess Scale-Up Facility in Preparation of Material for Phase II Studies


 
 
Announcements
Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
 
 
Facebook   Twitter
 
NPC
Privacy Policy Code of Ethics